ENDP
Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced...
Taking a quick look at the chart and analyzing volume, one can easily see the turnaround is soon to come. Look for a consistent price turnaround in the month of July (2018). The confirmed turnaround should occur early-mid August (2018). What do I know right???
Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018.
Although the clinical trial's success was...
Prudent Drug Discovery Company
Low market cap ( appox £13m at time of writing ).
Issues shares very rarely ( last placing nearly four years ago ).
Has material interest in its work from larger partners ( Pharmaxis ).
Sold interest in LOXL2 programme for £5m to Pharmaxis in December.
Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains...
Good opportunity to buy a potential 3 wave in development with a natural stop loss at immediately prior low. One of the few bullish charts I've seen in the stock market recently.
Generally speaking we're all pretty aware that a "Buy & Hold" strategy works well. Yet, we find outselves "trading". Despite the evidence indicating this is unwise.
In a snapshot view we can take a look at the daily chart (nearly a years worth) and view our 3 stocks in the Biotech basket - and we can pick up some obvious patterns.
These stocks are very much...
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as
INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder...
NASDAQ:MYL is breaking out of a wedge that it has been consolidating in for nearly four years. This wedge appears to be a retest of the breakout from resistance that occurred in 2013, which was followed by a large rally during the "biotech bubble". I expect the wedge breakout to take us back to the all-time highs, at a minimum, and potentially to...
Itus Corporation, a company that develops, aquires, and licenses emerging technologies in the areas of biotechnology, is in the stages of developing technology that can detect cancer at an earlier rate through a blood test. The company saw its stock jump by 85 percent upon releasing news of the patent issuance of the new technology, this was on Sept. 18.
The...
from what I see what happened today was in the chart it's just the knee jerk reaction was a bit of a pain to watch. arrows point resistance levels and trend was bought up to that line of support after the rug pull. i don't personally see a trend change here yet. comments welcome as always.
Immuno-oncology stock that has recently completed an offering of common stock @ $0.75 per share. Stock looks to have bottomed out. Buy a for a potential 10-20% bounce.
Celgene is one of my top picks in the biotech sector, it is fundamentally strong, and the chart is providing a great potential breakout picture.
I have entered half of my position around 127.50$ and looking to add around 123$ with a hard stop below 116$ below 115$ there is a chance that we get back to 100$ though i am not expecting this scenario right now. Targets...
Textbook breakout and retest, this can be a multimonth opportunity.
In the coming days i will analyse some biotech stocks, where i am seeing good potential for a trade.
